Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial / American Association for Cancer Research

Kathleen Medora / aacr - Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with…

#healthcare #pharmaceuticals #drugdevelopment

Highlights from ABC 8 – International Consensus Guidelines for Advanced Breast Cancer Management

2 months / oncodaily

Deep Dive Into the Latest Consensus on Advanced Breast Cancer Management – SPCC

2 months / oncodaily

Abdu Adem Yesufe: Advanced HER2+ Breast Cancer Treatments Remain Out of Reach for LMICs

2 months / oncodaily

The Potential of Tucatinib as a First-Line Maintenance Therapy Option in HER2+ MBC – Sarah Cannon Research Institute

2 months / oncodaily

Adding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancer

3 months / medicalxpress

Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial

3 months / aacr / Kathleen Medora

Saturday, December 13, 2025, 4:21 am / permalink 16917 / 6 stories in 2 months



Related Stories



Related Tags


Healthcare

Judge orders Leapfrog to remove safety grades for five Florida hospitals (22 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (41 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #healthcare


Pharmaceuticals

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

more #pharmaceuticals


Drug Development

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

Cancer Grand Challenges awards five teams bold funding for cancer research (4 days)

Belzutifan combinations highlighted at ASCO GU improve RCC outcomes (4 days)

more #drugdevelopment


StackHealth Time Machine



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.